



Copyright © 2017 Kansara *et al*

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/2.0>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

ORIGINAL RESEARCH

Endocrine and Non-Endocrine Consequences in Women with Polycystic Ovary Syndrome

Mudra H KANSARA¹, Mandava V RAO^{1,2*}, Himanshu BAVISHI³

¹Gujarat Genetic Diagnostic Center (GenDiCe), Department of Zoology, University School of Sciences, Gujarat University

²Supratech Micropath Laboratory and Research Institute, Ahmedabad, Gujarat

³Bavishi Fertility Institute, Nr. Adani CNG Station, Opp Municipal Garden, Ahmedabad-380007, Gujarat

*Corresponding Author email: manvrao@gmail.com

• Received: 09 October 2016 • Revised: 02 December 2016 • Accepted: 13 December 2016 • Published: 17 December 2016 •

ABSTRACT

Polycystic ovarian syndrome (PCOS) is the most common hormonal abnormality in reproductive age of women. The features of PCOS include increased androgen production and disordered gonadotropin secretion leading to menstrual irregularity and infertility. In addition, 40-80% of women with this condition are reported to be overweight or obese. In our study of 50 cases with closely matched age groups, we evaluated hormonal levels and non-endocrine factors like serum lipid peroxidation (LPO), superoxide dismutase (SOD), obesity and age. Alteration in hormones in different age groups (20-30, 31-40 and 41-50 years) was detected with changes in LPO and SOD levels comparatively. Similarly, obesity is an indicative of higher BMI values. These altered endocrine, oxidative stress and elevated BMI indicators are associated with this pathological condition. Among preventive measures/strategies, such cases are suggested to undergo regular exercises and promoting healthy lifestyles, based on diet on long term basis as effective therapies or to have metabolic surgery to restore fertility.

KEY WORDS: PCOS subjects, Age, Hormones, Obesity, Oxidative stress

Introduction

Female infertility affects an estimated 48 million women with the highest prevalence of infertility affecting people in South Asia, Sub-Saharan Africa, North Africa/Middle East, and Central/Eastern Europe and Central Asia (Mascarenhas *et al.*, 2012). There are few medical conditions such as polycystic ovarian syndrome (PCOS), endometriosis, bad obstetric history (BOH), ovarian failure (OF), fibroids, tubal defect etc., which can lead to female infertility in addition to genetic and environmental factors (Papalou *et al.*, 2016). Amongst all these disorders, PCOS is one of the most common disorders among females. It is a complex and heterogeneous endocrine disorder with well-established metabolic abnormalities. The World Health Organization estimates that it affects 116 million women (3.4% of women)

worldwide (Vos *et al.*, 2012). The prevalence of PCOS in India is from 2.2% to 26% (Shirsath *et al.*, 2015). It is an anovulatory cause of infertility affecting 6-10% of premenopausal women (Antoaneta *et al.*, 2015). Hyperandrogenism, oligomenorrhea and chronic anovulation are common clinical manifestations of PCOS women (Norman *et al.*, 2007). Alterations in several metabolic pathways have been implicated in the pathophysiology of it, including abnormalities in steroid hormone regulation and insulin signaling pathways (Azziz, 2002). Although there is no consensus as to an explanation of the biological mechanisms behind PCOS, its altered hypothalamic-pituitary-ovarian (HPO) axis brings about irregularities of normal hormonal regulation and folliculogenesis (Jonard *et al.*, 2004). This condition is able to create

hyperandrogenism, hyperestrogenism and altered gonadotropin levels followed by other related factors like hyperinsulinemia triggering a reduction of sex hormone binding globulin (SHBG) (Barontini *et al.*, 2001 ; Lim *et al.*, 2016).

Obesity has been linked to abnormal function of the hypothalamic-pituitary-ovarian (HPO) axis through multiple mechanisms that contribute to a development of PCOS. Multiple other growth factors and inflammatory conditions are increased in obese women (Legro, 2012). The imbalance between the production of reactive oxygen species (ROS) and the antioxidant defense system produces the oxidative damage leading to oxidative stress (OS). Reactive oxygen species can affect a variety of physiological functions in the reproductive tract, when ROS/RNS increase to pathological levels like in PCOS (Zuo *et al.*, 2016). These are capable of inflicting significant damage to cell structures inducing this condition. Hence, we have undertaken biochemical and endocrine analysis in three age groups of PCOS in Gujarat as these people adopt various western lifestyles in addition to other stress factors.

Materials and Methods

Selection of patients

Patients diagnosed as PCOS at Bavishi Fertility Institute, Ahmedabad were selected for the study. The consents were taken from the patients prior to study and the objectives of the study were also explained. A specific proforma was designed to collect the details of personal, medical and reproductive history. In personal history age, age at marriage, information of menstrual cycle, medical history of family, pedigree, weight, height and other information were recorded. These subjects (50) within the age of 20 to 50 years were selected and divided into three age groups i.e. 20-30 yrs, 31-40 yrs and 41-50 yrs. The blood samples were collected and centrifuged at 2000 rpm for 10 min, clear serum was used for the analysis of endocrine and antioxidant indices along with BMI values. This work was approved by local Human Ethical Committee (HEC) of Gujarat University. (GU./HEC001/2015), Ahmedabad.

Hormonal studies

The hormones evaluated in the patients were follicle stimulating hormone (FSH), luteinizing hormone (LH), estradiol (E2), progesterone (P) and testosterone (T)

hormones. This analysis was carried out by Chemiluminescence technique using Architect instrument. The units of these gonadotropins are mIU/ml (Veeresh *et al.*, 2015) and units of steroids are pg/ml for estradiol (E2), ng/dl for testosterone (T) (González *et al.*, 2012) and ng/ml for progesterone (P) (Phipps *et al.*, 2000).

Analysis of SOD and lipid peroxidation (LPO)

The activity of superoxide dismutase (SOD) was assayed by the modified spectrophotometric method of Kakkar *et al.* (1984). Its levels were expressed as units of enzymatic activity per mg of protein contained in the samples (U/mg protein). The thiobarbituric acid reactive species (TBARS) levels were determined by the modified method of Buege and Aust (1978) and the values were expressed in units of nmol/ml.

BMI values

The body mass (weight) and height of an individual were recorded. We calculated the BMI by dividing the body mass by the square of the body height and expressed in units of kg/m² (Seleem *et al.*, 2014). All these values were statistically analyzed using GraphPad Prism software 5.03. The value of P<0.05 is considered significant.

Results

We enrolled 50 PCOS cases followed by 40 subjects in control group ranging in age from 20-50 yrs. and divided them in 20-30, 31-40 and 41-50 yrs in our study. BMI values were increased significantly (P<0.05) in our data. Similarly the anti-stress factors like SOD levels were decreased (P<0.05), whereas LPO levels were increased (P<0.05) markedly in our study, but no difference in average age was noticed (Table 1).

Table 1: BMI and anti-stress indices in control and PCOS groups

Parameter	Control (40)	PCOS (50)
Age (yrs)	29.22 ± 1.55	32.13 ± 1.87 ^{ns}
BMI (kg/m ²)	21.06 ± 0.51	26.66 ± 0.72 [*]
LPO (nmol/ml)	2.72 ± 0.18	5.45 ± 0.26 [*]
SOD activity (U/mg protein)	5.75 ± 0.38	2.35 ± 0.14 [*]

All the values are Mean ± SE. * = p< 0.05; ns = Non Significant

Gonadotropin profiles

The gonadotropin (LH and FSH) levels were altered in three

age groups (20-30, 31-40 and 41-50 yrs) of patients. FSH levels were more in old aged groups, which were significant ($P < 0.05$) in our study. Similarly, LH levels were also found to be increased ($P < 0.05$) (Figs. 1 and 2).




Figure 1: FSH (mIU/ml) profile in controls and PCOS age groups (All the values are Mean ± SE. * = $p < 0.05$; ** = $p < 0.005$; ns = Non Significant)




Figure 2: LH (mIU/ml) profile in age groups of controls and PCOS (All the values are Mean ± SE. * = $p < 0.05$; ** = $p < 0.005$)

Steroid hormone profiles

Serum E2 levels were higher ($P < 0.005$) in old aged patients. Testosterone levels were also higher ($P < 0.05$) in all age groups. Serum progesterone (P) levels however were not raised in our study (Figs. 3-5).

Discussion

Our study indicated that hormonal milieu was changed, as circulating gonadotropin levels were increased with age, indicating a direct correlation with age in our study, though mean age was not significant with control subjects. Similarly

E2 and T levels followed the same condition, where hyperandrogenism and hyperestrogenism were correlated with a function of age. It is a well established fact that HPO axis undergoes changes with an altered secretion of hypothalamic neurons (GnRH) leading to elevated LH and FSH levels which in turn bring about higher levels of steroid hormones in blood of PCOS women. Due to this condition folliculogenesis is affected creating anovulation and menstrual irregularity (Bungum *et al.*, 2013; Dasgupta *et al.*, 2013). Majority of women with PCOS also experience ovarian dysfunction presenting oligomenorrhoea and amenorrhoea (Teede *et al.*, 2010). Hyperandrogenism is a predictor for hyperinsulinemia where glucose metabolism is affected. As a result, insulin resistance brings about disturbed metabolic effects (Duleba, 2012) to support our data. Increased estrogen levels in our study are also explained by conversion of hypothalamic and adipose tissue aromatase from androgen to estrogen in PCOS patients (Legro, 2012 ; Papalou *et al.*, 2016) in support of our report.




Figure 3: Estradiol (E2) levels (pg/ml) in age groups (All the values are Mean ± SE. ** = $p < 0.005$; ns = Non Significant)

Further hyperandrogenism initiates metabolic syndrome, hirsutism, cardiovascular risk and obesity in PCOS patients (Benson *et al.*, 2008 ; Lim *et al.*, 2016). In our population, obesity is also confirmed by higher values of BMI, which is not a cause of PCOS induction. But it is able to exacerbate PCOS along with insulin resistance, metabolic risks, hyperandrogenism and cardiovascular disturbances and reduction in SHBG with cellular inflammation (Teede *et al.*, 2010 ; Legro, 2012) in light of our data. PCOS etiology is much unclear, though several factors are involved in its

induction to cause infertility. One of the factors is an increasing oxidative stress in PCOS that induces genomic and mitochondrial DNA damage leading to sterility in these cases. The superoxide dismutase (SOD) is able to catalyze the conversion of superoxide to elevated O₂ and H₂O₂. The latter further gets converted to H₂O by catalase to provide protection to the cells (Tejasvi *et al.*, 2014). In our case, its levels were reduced indicating its role in prevention of oxidative stress (OS) in our obese cases




Figure 4: Testosterone (T) levels in all age groups (ng/dl) (All the values are Mean ± SE. * = p< 0.05)

Our results were in agreement with Zhang *et al.*, (2008), who support systemic that OS is contributory for this dysfunction. Further OS is substantiated by continuous increase in lipid peroxidation (LPO) levels. LPO levels also called TBARS complexes, a marker of malonyldialdehyde dominated oxidation of polyunsaturated fatty acids (PUFS) in endocrinocytes of obese cases (Shirsath *et al.*, 2015 ; Zuo *et al.*, 2016 ; Papalou *et al.*, 2016).




Figure 5: Progesterone (P) profile in all age groups of controls and PCOS (ng/ml) (All the values are Mean ± SE. ns = Non Significant)

This elevated oxidative stress could lead to continuous production of ROS/ RNS that creates cellular damage affecting hypothalamic-pituitary-ovarian (HPO) axis function in subjects of PCOS in comparison to age matched control women in our study (Seleem *et al.*, 2014 ; González *et al.*, 2012 ; Escobar-Morreale, 2012). Papalou *et al.* (2016) also argued that OS in conjunction with the rest etiologic mechanisms of PCOS results in an adverse redox status and stigmatizes the process of this syndrome.

Our study hence concludes that PCOS is caused by altered endocrine status notably with age, obesity, and systemic oxidative stress in females affecting fertility. This condition is controlled by adopting healthy lifestyles, restricted diet, proper sleep and daily exercises on long term basis (Zuo *et al.*, 2016) or to undergo surgery for restoration of fertility depending on severity of obesity in these women.

Acknowledgements

This work is supported by Gujarat State Biotechnology Mission (GSBTM), Gandhinagar. Support from other faculty at Medical Institute is well appreciated.

References

Antoaneta, G., Kamenov, Z. and Tsakova, A. (2015) Myeloperoxidase Levels in Patients with PCOS and/or Obesity Before and After Metformin Treatment. *International Journal of Women's Health and Reproduction Sciences*, 3(1):21–24.

Avinash Tejasvi, M. L., Bangi, B. B., Geetha, P., Anulekha Avinash, C. K., Chittaranjan, B., Bhayya, H. and Donempudi, P. (2014) Estimation of serum superoxide dismutase and serum malondialdehyde in oral submucous fibrosis: a clinical and biochemical study. *Journal of Cancer Research and Therapeutics*, 10(3):722-725.

Azziz, R. (2002) Polycystic ovary syndrome, insulin resistance, and molecular defects of insulin signaling. *The Journal of Clinical Endocrinology and Metabolism*, 87(9):4085-4087.

Barontini, M., Garcia-Rudaz, M. C. and Veldhuis, J. D. (2001) Mechanisms of hypothalamic-pituitary-gonadal disruption in polycystic ovarian syndrome. *Archives of Medical Research*, 32(6):544-552.

Benson, S., Janssen, O. E., Hahn, S., Tan, S., Dietz, T., Mann, K., Pleger, K., Schedlowski, M., Arck, P. C. and Elsenbruch, S. (2008) Obesity, depression, and chronic low-grade inflammation in women with polycystic ovary syndrome. *Brain, Behavior and Immunity*, 22(2):177-184.

Buege, J. A. and Aust, S. D. (1978) Microsomal lipid peroxidation. *Methods in Enzymology*, 52:302-310.

Bungum, L., Franssohn, F., Bungum, M., Humaidan, P. and Giwercman, A. (2013) The circadian variation in Anti-Müllerian hormone in patients with polycystic ovary syndrome differs significantly from normally ovulating women. *PLoS One*, 8(9):e68223.

Dasgupta, A., Khan, A., Banerjee, U., Ghosh, M., Pal, M., Chowdhury, K. M. and Dasgupta, S. (2013) Predictors of insulin resistance and metabolic complications in polycystic ovarian

- syndrome in an eastern Indian population. *Indian Journal of Clinical Duleba, A. J.* (2012) Medical management of metabolic dysfunction in PCOS. *Steroids*, 10;77(4):306-311.
- Escobar-Morreale, H. F. (2012) Surgical management of metabolic dysfunction in PCOS. *Steroids*, 10;77(4):312-316.
- González, F., Sia, C. L., Stanczyk, F. Z., Blair, H. E. and Krupa, M. E. (2012) Hyperandrogenism exerts an anti-inflammatory effect in obese women with polycystic ovary syndrome. *Endocrine*, 42(3):726-735.
- Jonard, S. and Dewailly, D. (2004) The follicular excess in polycystic ovaries, due to intra-ovarian hyperandrogenism, may be the main culprit for the follicular arrest. *Human Reproduction Update*, 10(2):107-117.
- Kakkar, P., Das, B. and Viswanathan, P. N. (1984) A modified spectrophotometric assay of superoxide dismutase. *Indian Journal of Biochemistry & Biophysics*, 21(2):130-132.
- Legro, R. S. (2012) Obesity and PCOS: implications for diagnosis and treatment. *Seminars in Reproductive Medicine*, 30(6):496-506.
- Lim, A. J., Huang, Z., Chua, S. E., Kramer, M. S. and Yong, E. L. (2016) Sleep Duration, Exercise, Shift Work and Polycystic Ovarian Syndrome-Related Outcomes in a Healthy Population: A Cross-Sectional Study. *PLoS One*, 11(11):e0167048.
- Mascarenhas, M. N., Flaxman, S. R., Boerma, T., Vanderpoel, S. and Stevens, G. A. (2012) National, regional, and global trends in infertility prevalence since 1990: a systematic analysis of 277 health surveys. *PLoS Medicine*, 9(12):e1001356.
- Norman, R. J., Dewailly, D., Legro, R. S. and Hickey, T. E. (2007) Polycystic ovary syndrome. *The Lancet*, 25;370(9588):685-697.
- Papalou, O., Victor, V. M. and Diamanti-Kandarakis, E. (2016) Oxidative Stress in Polycystic Ovary Syndrome. *Current Pharmaceutical Design*, 22(18):2709-2722.
- Biochemistry*, 28(2):169-176.
- Phipps, M. G., Hogan, J. W., Peipert, J. F., Lambert-Messerlian, G. M., Canick, J. A. and Seifer, D. B. (2000) Progesterone, inhibin, and hCG multiple marker strategy to differentiate viable from nonviable pregnancies. *Obstetrics and Gynecology*, 95(2):227-231.
- Seleem, A. K., El Refaeey, A. A., Shaalan, D., Sherbiny, Y. and Badawy, A. (2014) Superoxide dismutase in polycystic ovary syndrome patients undergoing intracytoplasmic sperm injection. *Journal of Assisted Reproduction and Genetics*, 31(4):499-504.
- Shirsath, A., Aundhakar, N. and Kamble, P. (2015) Study of oxidative stress and antioxidant levels in polycystic ovarian disease. *International Journal of Healthcare and Biomedical Research*, 3(4):04;16-24.
- Teede, H., Deeks, A. and Moran, L. (2010) Polycystic ovary syndrome: a complex condition with psychological, reproductive and metabolic manifestations that impacts on health across the lifespan. *BioMed Central Medicine*, 30;8:41.
- Veeresh, T., Moulali, D. and Sarma, D. V. H. S. (2015) A Study on Serum FSH, LH and Prolactin Levels in Women with Thyroid Disorders. *International Journal of Scientific and Research Publications*, 5(3):1-4.
- Vos, T., Flaxman, A., Naghavi, M., Lozano, R., Michaud, C. and Ezzati, M. (2012) Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. *The Lancet*, 380 (9859):2163–2196.
- Zhang, D., Luo, W. Y., Liao, H., Wang, C. F. and Sun, Y. (2008) The effects of oxidative stress to PCOS. *Journal of Sichuan University, Medical Science Edition*, 39(3):421-423.
- Zuo, T., Zhu, M. and Xu, W. (2016) Roles of Oxidative Stress in Polycystic Ovary Syndrome and Cancers. *Oxidative Medicine and Cellular Longevity*, 2016:1-14.